Personalis Inc. Raises Full-Year Revenue Guidanceby Mark Eisenberg 08.08.2024Personalis sees 35% Q2 revenue growth, lifts full-year outlook to $79-$81M.
Vinci Partners’ Strategic Growth in Q2 2024 Earningsby Mark Eisenberg 08.08.2024Vinci Partners reports R$61.9M fee earnings; expands private market strategies. Dividend declared amid challenging macroeconomic climate.
Kellanova Stock Target Raised Amid M&A Speculationby Mark Eisenberg 08.08.2024Kellanova's stock target increased to $73 by TD Cowen due to merger and acquisition potential despite recent challenges.
Exscientia and Recursion Merge to Form AI Drug Discovery Giantby Lilu Anderson 08.08.2024Exscientia merges into Recursion to form a $850 million AI drug discovery powerhouse, focusing on oncology and rare diseases.
Robinhood’s Futures Trading: Potential Challenges Aheadby Mark Eisenberg 08.08.2024Robinhood faces hurdles in futures trading with possible fees, impacting its commission-free model, J.P. Morgan warns.
Bitcoin Price Surges Amid ETF Inflows and Investor Confidenceby John Darbie 08.08.2024Bitcoin surpasses $57,000 with ETF inflows; institutional backing boosts confidence.
Tech Sell-Off Echoes 1987 Crash: Societe Generaleby Mark Eisenberg 08.08.2024Rising recession fears and tech stock volatility mirror the 1987 market crash, warns Societe Generale.
Ripple’s Legal Win: A Turning Point for Crypto Regulationby John Darbie 08.08.2024Ripple's legal victory against the SEC could reshape cryptocurrency regulations and boost investor confidence.
Top 3 Biotech Stocks to Buy for August 2024by Lilu Anderson 08.08.2024Explore promising biotech stocks like Vertex, Pfizer, and Merck, ready to innovate and grow in the evolving healthcare landscape.
Biotech Stocks to Buy in Market Downturnby Lilu Anderson 08.08.2024Explore top biotech stocks poised for growth amid market challenges. Learn about innovations and opportunities in gene therapy.